tetano
Editor, Senior Moderator
Pharmaceuticals (Basel)
. 2022 Sep 9;15(9):1127.
doi: 10.3390/ph15091127.
Antigenic Characterization of Neuraminidase of Influenza A/H7N9 Viruses Isolated in Different Years
Yulia Desheva[SUP] 1 [/SUP], Igor Losev[SUP] 1 [/SUP], Nadezhda Petkova[SUP] 1 [/SUP], Polina Kudar[SUP] 1 [/SUP], Svetlana Donina[SUP] 1 [/SUP], Andrey Mamontov[SUP] 1 [/SUP], Chih-Hsuan Tsai[SUP] 2 3 [/SUP], Yu-Chan Chao[SUP] 2 4 5 [/SUP]
Affiliations
Abstract
Influenza outbreaks caused by A/H7N9 viruses have occurred since 2013. After 2016, A/H7N9 influenza viruses underwent evolutionary changes. In this study, we examined the antigenic properties of influenza neuraminidase (NA) of A/H7N9 viruses as part of a live influenza vaccine (LAIV). It was shown that neuraminidase inhibiting (NI) antibodies obtained after A/Anhui/1/2013(H7N9)-based LAIV vaccination did not inhibit A/Hong Kong/125/2017(H7N9) NA and vice versa. The A/Hong Kong/125/2017(H7N9)-based LAIV elicited higher levels of NI antibodies compared to the A/Anhui/1/2013(H7N9)-based LAIV after two doses. Thelow degree of coincidence of the antibody response to hemagglutinin (HA) and NA after LAIV vaccination allows us to consider an enzyme-linked lectin assay (ELLA) as an additional measure for assessing the immunogenicity of influenza vaccines. In mice, N9-reactive monoclonal antibodies (mABs) for the A/environment/Shanghai/RL01/2013(H7N9) influenza virus partially protected against lung infection from the A/Guangdong/17SF003/2016 IDCDC-RG56N(H7N9) virus, thus showing the cross-protective properties of monoclonal antibodies against the drift variant.
Keywords: antibodies; influenza A/H7N9; live influenza vaccine; monoclonal antibodies; neuraminidase.
. 2022 Sep 9;15(9):1127.
doi: 10.3390/ph15091127.
Antigenic Characterization of Neuraminidase of Influenza A/H7N9 Viruses Isolated in Different Years
Yulia Desheva[SUP] 1 [/SUP], Igor Losev[SUP] 1 [/SUP], Nadezhda Petkova[SUP] 1 [/SUP], Polina Kudar[SUP] 1 [/SUP], Svetlana Donina[SUP] 1 [/SUP], Andrey Mamontov[SUP] 1 [/SUP], Chih-Hsuan Tsai[SUP] 2 3 [/SUP], Yu-Chan Chao[SUP] 2 4 5 [/SUP]
Affiliations
- PMID: 36145348
- DOI: 10.3390/ph15091127
Abstract
Influenza outbreaks caused by A/H7N9 viruses have occurred since 2013. After 2016, A/H7N9 influenza viruses underwent evolutionary changes. In this study, we examined the antigenic properties of influenza neuraminidase (NA) of A/H7N9 viruses as part of a live influenza vaccine (LAIV). It was shown that neuraminidase inhibiting (NI) antibodies obtained after A/Anhui/1/2013(H7N9)-based LAIV vaccination did not inhibit A/Hong Kong/125/2017(H7N9) NA and vice versa. The A/Hong Kong/125/2017(H7N9)-based LAIV elicited higher levels of NI antibodies compared to the A/Anhui/1/2013(H7N9)-based LAIV after two doses. Thelow degree of coincidence of the antibody response to hemagglutinin (HA) and NA after LAIV vaccination allows us to consider an enzyme-linked lectin assay (ELLA) as an additional measure for assessing the immunogenicity of influenza vaccines. In mice, N9-reactive monoclonal antibodies (mABs) for the A/environment/Shanghai/RL01/2013(H7N9) influenza virus partially protected against lung infection from the A/Guangdong/17SF003/2016 IDCDC-RG56N(H7N9) virus, thus showing the cross-protective properties of monoclonal antibodies against the drift variant.
Keywords: antibodies; influenza A/H7N9; live influenza vaccine; monoclonal antibodies; neuraminidase.